Eli Lilly and Company has publicly denied any partnership with telehealth provider Mangoceuticals for the distribution of its popular weight-loss medications. This statement came after Mangoceuticals had announced a collaboration with both Eli Lilly and Novo Nordisk on November 13, which caused a temporary surge in Mangoceuticals' stock price. Lilly's swift rebuttal was crucial to clarifying the supply and prescription channels for its high-demand drugs. The company did note that any healthcare provider, including those on telehealth platforms, can prescribe their medicines and have them fulfilled through LillyDirect, but it emphasized the absence of a formal partnership with Mangoceuticals. The news brought Mangoceuticals' stock back down after its initial spike.